| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 2 | |||
| NCT03340129 | Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) | Melanoma Stage Iv | Recruiting |
| NCT06151236 | Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma | Merkel Cell Carcinoma | Recruiting |
| NCT06999980 | Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation) | Cutaneous Melanoma | Recruiting |
| NCT06767306 | Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic… | Melanoma Metastatic | Recruiting |
| NCT06288191 | Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma | Recruiting |
| NCT02374242 | Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases | Melanoma | Active, Not Recruiting |
| NCT05418972 | A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical… | Stage II Melanoma | Active, Not Recruiting |
| NCT04207086 | A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III… | Melanoma Stage III | Active, Not Recruiting |
| Not specified | |||
| NCT06536257 | Personalised Immunotherapy Platform | Melanoma | Recruiting |
| NCT07049276 | The Multicentre Selective Lymphadenectomy Trial - 3 | Cutaneous Melanoma, Stage III | Recruiting |